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A B S T R A C T   
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is able to produce an excessive host 
immune reaction and may leads to severe disease- a life-threatening condition occurring more often in patients 
suffering from comorbidities such as hypertension, diabetes and obesity. Infection by human corona viruses 
highly depends on host microRNA (miR) involved in regulation of host innate immune response and 
inflammation-modulatory miR-146a is among the first miRs induced by immune reaction to a virus. Moreover, 
recent analysis showed that miR-146 is predicted to target at the SARS-CoV-2 genome. As the dominant regulator 
of Toll-like receptors (TLRs) downstream signaling, miR-146a may limit excessive inflammatory response to 
virus. Downregulation of circulating miR-146a was found in diabetes, obesity and hypertension and it is reflected 
by enhanced inflammation and fibrosis, systemic effects accompanying severe COVID-19. Thus it could be hy-
pothesized that miR-146a deficiency may contribute to severe COVID-19 state observed in diabetes, obesity and 
hypertension but further investigations are needed.   
Background 
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection is able to produce an excessive host immune reaction and 
sometimes leads to severe disease- a life-threatening pneumonia and 
acute respiratory distress syndrome (ARDS). ARDS is characterized by 
elevated proinflammatory cytokines such as tumor necrosis factor α 
(TNF-α) and interleukins: IL-1β, IL-6, monocyte chemoattractant protein 
1 (MCP1), an increased incidence of shock and adverse clinical out-
comes [1]. Risk for developing severe and critical state of COVID-19 was 
found to be more likely in patients suffering from comorbidities such as 
hypertension and diabetes/obesity [2] yet underlyng mechanisms still 
not elucidated. Infection by human corona viruses as well as other res-
piratory viruses highly depends on host microRNA (miR) involved in 
maintaining the epithelial cell barrier in the respiratory tract and 
regulation of virus entry and replication [3]. MicroRNAs (miRs) are 
small (20–22 nucleotides), non-coding RNAs involved in the post-
transcriptional negative regulation (suppression) of target genes 
expression. Around two–thirds of human mRNAs are predicted to be 
regulated by miRs and while single miR can regulate different mRNAs, 
each mRNA could possibly be regulated by a huge number of miRs [4]. 
Mature miRs are deriving from primary transcripts which are processed 
in the nucleus by microprocessor complex (Drosha/DGCR8/RNASEN), 
exported to cytoplasm mainly through interaction with Exportin-5, 
where finally is processed via Dicer enzyme [5]. Circulating/extracel-
lular miRs, found in diverse body fluids, are highly stable due to their 
encapsulation within exosomes, microvesicles and apoptotic bodies or 
complex with high-density lipoproteins and Argonaute2. In this way, 
they are able to reach distant tissues cells and alter gene expression [6]. 
Moreover, it has been proposed that circulating miRs as epigenetic 
regulators are able to disseminate pathophysiological epigenetic signa-
ture from one host cell to another, neighbor or distant cells, a phe-
nomenon defined as epigenetic damage transmission [7]. miR-146a is 
abundantly expressed in mammals, is among the first miRs induced 
during immune activation and considered to be a dominant, negative 
regulator of the innate immune response [8]. The circulating-exosomal 
miR-146a is able to modulate the antiviral response in the recipient cell, 
acting as a critical factor for the development of viral infection [9]. 
Hypothesis 
Downregulation of miR-146 observed in diabetes, obesity and 
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hypertension may contribute to severe COVID-19 due to a promotion of 
excessive cytokine production and lack of feed-back mechanism to limit 
inflammatory damage of tissues. 
Diabetes/obesity and cardiovascular disease are risk factors for 
severe COVID-19 and are associated with circulatory miR-146a 
downregulation 
Among the first studies published, Wang et al. observed that in a 
cohort of 138 hospitalized patients with COVID-19, hypertension 
(31.2%), diabetes (10.1%), cardiovascular disease (14.5%) and malig-
nancy (17.2%) were the most common coexisting medical conditions 
[10]. Meta-analysis performed by Li et al calculated an odds ratio of 2.2 
for diabetic patients to be admitted to an intensive care unit [11]. In 
another study, diabetes was found to be associated with the occurrence 
of ARDS with a hazard ratio of 2.3 [12]. Likewise, 47.6% of patients 
admitted to the intensive care unit in France and 48% of the patients 
admissions to intensive care in Spain due to SARS-CoV-2 were obese 
[13,14]. Furthermore, young patients developing severe forms of the 
infection, were more likely to have obesity [15]. Patients with hyper-
tension and SARS-CoV-2 infection expressed 2.27- and 3.48-fold higher 
risks of severity and fatality respectively compared to the COVID-19 
patients without hypertension [16]. Results of meta-analysis revealed 
that circulatory miR-146a was downregulated in T2D samples (PBMCs 
and whole blood samples) compared with controls [17]. Overweight and 
obesity, independent of other cardiometabolic risk factors, negatively 
influence circulating miR-146a, and miR-146a shows significant inverse 
relationship to body mass index [18]. Hypertension, independent of 
other cardiometabolic risk factors, adversely affects the circulating miR- 
146a which is inversely related to both systolic and diastolic blood 
pressure [19]. 
miR-146a defficiency is associated with excessive inflammation 
and modulation of host antiviral response 
Accumulating evidence suggests that chronic inflammation underlies 
obesity, diabetes and atherosclerotic coronary disease. Crucial player in 
this chronic inflammation is the feed-forward loop involving Nuclear 
Factor kappa-light-chain-enhancer of activated B cells (NF-κB), which 
increases pro-inflammatory cytokines such as TNF-α, IL-1, IL-6, and IFN- 
γ which, in turn, stimulate NF-κB [20]. miR-146a is induced in response 
to inflammation in order to attenuate inflammation: NF-κB-induces 
expression of miR-146a which negatively affects IL-1 and TNF-α re-
ceptors to attenuate inflammation [21]. Downregulation of circulatory 
miR-146a or miR-146a deficiency are associated with inflammatory 
disorders manifested in a various organs: lungs, heart, brain or skin, and 
underly vascular or autoimmune diseases (Table 1). Recognition of viral 
infection by pattern-recognition receptors, such as TLRs, initiates the 
innate immune response which includes changes in miRs expression and 
leads to modulation, augmentation or suppresion of cytokine responses. 
miR-146a is considered to be dominant regulator of TLR- downstream 
signaling [22]. Namely, miR-146a targets and suppresses several 
downstream TLR- signaling molecules, such as IL-1 receptor activated 
kinase 1 (IRAK1), interferon regulatory factor 5 (IRF5) and tumor re-
ceptor factor-associated factor 6 (TRAF6), in order to avoid excessive 
inflammation after infection [21]. Given its significance in host antiviral 
defense mechanisms, it is not surprising that virus could develop 
mechanisms of interfering with host miRs. In a study by Liu et al, among 
28 human miR predicted to target at the SARS-CoV-2 genome, miR-146 
was reported as one, involved in immunity modulation [23]. Virus could 
alter miR activity by binding and sequestering free miR or can alter miR 
expression and miR-mediated protein expression thus affecting viral 
replication and host immune responses. For example, IFN-signaling is a 
critical cascade of events induced by viral infection, leading to upre-
gulation of IFN-stimulated genes that inhibit viral replication. Viruses 
have developed various mechanisms to evade IFN system, such as 
through changes in host miR-146a. Namely, enterovirus- EV71, dengue 
virus, HBV or influenza A virus, by induction of miR-146a in infected 
cells, could negatively regulate the IFN-signaling [9,24]. Moreover, 
miR-146a negatively regulates IFN-γ production in natural killer cells 
(NK cells) by targeting IRAK1 and TRAF6, with subsequent inhibition of 
the NF-κB signaling cascade. IFN-γ is a critical cytokine produced by 
activated NK cells which function in immune defense to eradicate both 
virus-infected cells and tumor cells. However, it is observed that miR- 
146a suppressing effects occur only after NK cells receive excessive co- 
stimulation of IL-12 and IL-18 or become super active, suggesting that 
miR-146a induction would be initiated to “fine-tune” the immune 
response of NK cells into an appropriate range [25]. Likewise, it is also 
suggested that miR-146a may also negatively regulate cytotoxicity of NK 
cells [26]. In line with proposed protective role of miR-146a in SARS- 
CoV-2, Masselli et al. pointed out that upon SARS-CoV-2 infection, NK 
cells likely exit the peripheral blood, traffic into to the lung where 
potentially enhance local inflammation and injury [27]. Thus, miR-146a 
may, by “fine tuning” of NK cells, contribute to the balance between NK 
cells- beneficial antiviral and -detrimental pathologic effects in the lungs 
of COVID-19 patients. Furthermore, miR-146 deficiency observed in 
diabetes leads to enhanced inflammation (by insufficient inhibition of 
IRAK1/TRAF6), fibrosis (by fibronectin expression), and increased 
synthesis of MCP-1 followed by further reduction of miR-146a (by 
enhancing TGF-β1/ErbB4/Notch1 signaling) [28], systemic effects 
accompanying severe COVID-19 [1]. 
Conclusions 
Patients with diabetes, obesity and hypertension are associated with 
downregulation of circulating miR-146a and this dysregulation may be 
exacerbated by SARS-CoV-2 infection since virus might interfere with 
miR-146. Downregulation of miR-146a could be one of the factors un-
derlying severe COVID-19 due to an unadequate host antiviral response, 
showing more prolonged and excessive cytokine production and lack of 
feed-back mechanism to limit inflammatory damage of tissues. Future 
statistical verification of well-designed epidemiological studies is 
needed to determine correlation of circulating miR-146a deficiency and 
severe COVID-19 clinical state. Moreover, since miR activity and 
Table 1 
Association of miR-146a downregulation/deficiency with vascular and auto-
immune diseases.  




Downregulation of plasma 
miR-146a 
Poor coronary collateral circulation in 
patients with coronary artery disease 
[31] 
Downregulation of serum 
miR-146a 
Severe acute ischemic stroke [32] 
Downregulation of serum 
miR-146a 
Acute exacerbation of chronic 
obstructive pulmonary disease and 
negative correlation with inflammatory 
cytokines: TNF-α, IL-1β, IL-6, IL-8 
[33] 
Downregulation of PBMCs- 
derived miR-146a 
Severe systemic lupus erythematosus 
and the induction of type I IFNs 
[34]  
miR-146a-deficient mice 
Knockout of the miR-146a 
gene in C57BL/6 mice 
Myeloproliferative disease (myeloid 
and lymphoid malignancies) due to a 
lack of NF-kB suppression 
[35] 
Mice harboring miR-146a- 
deficient Treg cells 
Impaired function of Treg cells: no 
restraint of IFN-γ-mediated pathogenic 
Th1 responses and associated 
inflammation 
[36] 
Model of myocardial 
ischemia and reperfusion 
injury 
Decreased heart function and increased 
myocardial infarction and apoptosis by 
targeting Med 1 gene 
[37] 
Model of Atopic dermatitis Increased accumulation of infiltrating 
cells in the dermis, elevated expression 
of IFN-γ, CCL5 and CCL8 in the skin 
[38]  
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function could be modified in patients by pharmacological modulation, 
investigations should aim also at the possibility of correcting miR-146 
deficiency in order to improve host antiviral response in diabetes/ 
obesity and hypertension patients. Noteworthy, recent studies revealed 
that therapeutic effect of glucocorticoids, drugs which are used in severe 
COVID-19 treatment, is mediated via miR-146a [29], as well as that 
exogenous administration of miR-146a to human lung cells augments 
the effects of these drugs [30]. Having this in mind, it seems that miR- 
146a could have an impact on therapeutic regime of severe COVID-19 
patients by enhancing efficacy of glucocorticoid medications. 
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